Genmab A/S announced new results from Arm 10 of the Phase 1b/2 EPCORE NHL-2 trial, evaluating epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE). The study focused on adult patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) who are eligible for autologous stem cell transplantation (ASCT).
Results demonstrated an overall response rate (ORR) of 87 percent, with a complete response (CR) rate of 65 percent and a partial response (PR) of 23 percent. A significant majority of patients, 65 percent, proceeded to ASCT, indicating the therapy's effectiveness as a bridge to this potentially curative treatment.
At six months, an estimated 81 percent of responses were ongoing, 74 percent of patients were progression-free, and 100 percent of patients were alive. The safety profile showed cytokine release syndrome (CRS) to be low grade, with no discontinuations due to treatment-emergent adverse events, even in high-risk patients who progressed rapidly after initial treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.